Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
BLT | Good results ? | 22/04/24 | 1 | 716 | |||
|
|||||||
BLT | Benitec Biopharma's Oculopharyngeal Muscular Dystrophy ... | 14/02/24 | 1 | 797 | |||
|
|||||||
BLT | Letter received - YOUR IMMEDIATE ACTION IS REQUIRED PER DELAWARE UNCLAIMED PROPERTY LAWS | 11/12/23 | 2 | 1.3K | |||
|
|||||||
BLT | NEO Compensation | 03/12/23 | 7 | 4.2K | |||
|
|||||||
BLT | OPMD update | 04/07/23 | 5 | 2.1K | |||
|
|||||||
BLT | Morgan Stanley increases their stake to 5.2% | 21/10/21 | 1 | 1.5K | |||
|
|||||||
BLT | CSL and RNAi | 07/03/21 | 21 | 257K | |||
|
|||||||
BLT | Ann: Benitec Provides Update on BB-301 OPMD Program | 04/03/21 | 66 | 24K | |||
|
See All Discussions